
AQST Stock Forecast & Price Target
AQST Analyst Ratings
Bulls say
Aquestive Therapeutics Inc is well-positioned for future financial growth due to its promising pipeline in the no-needle epinephrine market and innovative alternatives for managing severe allergic reactions. Recent FDA announcements regarding the NDA of its product Anaphylm have contributed to a significant surge in share prices, reflecting heightened investor confidence in the company’s regulatory progress and market potential. With ongoing developments in its later-stage pipeline focused on Central Nervous System diseases and a robust commercial portfolio, Aquestive Therapeutics stands to capitalize on unmet medical needs, further enhancing its revenue prospects primarily in the United States.
Bears say
The outlook for Aquestive Therapeutics's stock is negatively influenced by significant risks related to the development of AQST-109, which may not succeed, potentially impacting future revenue projections. There is also a concern regarding a greater-than-expected decline in revenues from existing commercial products, which could undermine financial stability. Additionally, the need for the company to raise capital to bolster its balance sheet raises further red flags regarding its financial health and operational viability.
This aggregate rating is based on analysts' research of Aquestive Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
AQST Analyst Forecast & Price Prediction
Start investing in AQST
Order type
Buy in
Order amount
Est. shares
0 shares